Skip to content
Dosage GuideResearch Reference

SS-31 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for SS-31. All information is for educational purposes only.

Quick Answer

In clinical trials, SS-31 (Elamipretide) is typically administered at 40mg subcutaneously once daily or 0.1mg/kg intravenously. Dosing frequency and route vary depending on the specific clinical application. No human clinical dose-ranging trials exist outside of these established clinical protocols.

→ SS-31 Benefits→ SS-31 Side Effects→ Full SS-31 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 40 mg subcutaneous daily; 0.1 mg/kg intravenous

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Mitochondrial Dysfunction (General)

40 mg1× daily
Duration

4–12 weeks

Subcutaneous injection. Mimics dosing in Phase 2/3 clinical trials. May be used as a general mitochondrial support protocol.

Cardioprotection (Heart Failure)

40 mg1× daily
Duration

4–12 weeks

Subcutaneous injection. Dosing based on clinical trial protocols for heart failure. Monitor cardiac function.

Renal Protection (Ischemia-Reperfusion Injury)

0.1 mg/kgSingle dose
Duration

Single dose

Administered intravenously prior to anticipated ischemia-reperfusion event. Based on animal studies and some exploratory human data.

Barth Syndrome

40 mg1× daily
Duration

Ongoing

Subcutaneous injection. Used as chronic therapy in Phase 3 clinical trials. Requires careful monitoring by a qualified physician.

Age-Related Mitochondrial Decline

20-40 mg1-2x weekly
Duration

4-12 weeks

Experimental dosing for research purposes only. Subcutaneous injection. There is limited human data to support this indication.

Timing & Frequency

For general mitochondrial support and cardioprotection, subcutaneous injections are typically administered in the morning. Timing relative to meals is not critical. IV administration is often given prior to surgery or anticipated ischemic event.

Cycle Guidance

Clinical trials have used continuous daily administration for extended periods (several months). Research protocols typically cycle SS-31 for 8-12 weeks, followed by a 4-week break, though the necessity of cycling is not definitively established. Given limited long-term human safety data, cycling provides a conservative approach.

Reconstitution Reference

Quick reference for reconstituting SS-31. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 5 mg per vial
BAC Water Volume1 mL bacteriostatic water for 5 mg/mL concentration
Concentration & DrawAt 5 mg/mL: 40 mg = 8 mL (Use appropriate syringe for accurate measurement).
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable up to 30 days refrigerated. Lyophilized powder stable 12-24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard SS-31 dosage for mitochondrial support?
Based on clinical trial experience, 40 mg subcutaneously once daily is commonly used. Some research protocols may use lower doses (20 mg) or less frequent administration (2-3 times per week) for general support. Consult a qualified practitioner for personalized guidance.
How should SS-31 be administered?
The most common route of administration is subcutaneous injection. Intravenous administration is also used in some clinical settings. Intramuscular injection is possible but less common. Oral administration is not effective.
What are the potential side effects of SS-31?
SS-31 is generally well-tolerated in clinical trials. Common side effects include mild injection site reactions (redness, swelling, pain). Rarely, more serious side effects such as allergic reactions or changes in liver enzymes may occur. Report any adverse effects to your healthcare provider.
Can SS-31 be taken with other medications?
It is important to discuss all medications and supplements with your healthcare provider before starting SS-31. There are no known major drug interactions, but potential interactions should be considered on a case-by-case basis.
How long does it take to see results with SS-31?
The onset of effects can vary depending on the individual and the specific condition being treated. Some individuals may experience noticeable improvements within a few weeks, while others may require several months of treatment to see significant benefits. Consistent adherence to the prescribed dosage is important for optimal results.

Last updated: 2026-02-19